HIV

New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output. Read More

Vanderbilt researchers find that heterosexually active Black males are the least likely to establish HIV care within one month of diagnosis and suggest that targeted interventions focus on this population. Read More

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes. Read More

HIV-1, the virus that causes AIDS, exploits inositol phosphates in T cells to aid its own assembly and maturation — suggesting that targeting inositol phosphate binding could inhibit HIV-1 replication. Read More

Technology may be a viable option for reducing HIV risk for African Americans in rural communities, according to a new Vanderbilt report.  Read More

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus. Read More

The recent decriminalization of homosexuality in Mozambique has not made it easier for LGBT advocacy groups to support these populations within the country. Read More

When chronic disease patients let their care lapse and fail to show for clinic appointments, it may behoove clinics to reach out and encourage a return to care. Read More

Researchers in the Vanderbilt Institute for Global Health (VIGH) have received two new grants from the National Institutes of Health (NIH) aimed at reducing the risk of kidney disease in HIV-infected adults and improving the treatment of epilepsy in children in Nigeria. Read More

Nine more volunteers are needed to complete a study at Vanderbilt University Medical Center (VUMC) that could lead to a way to prevent the spread of HIV (human immunodeficiency virus). Read More

Rates of new HIV infections in the United States are declining — except among men who have sex with men. Rates are particularly high among African-American and Hispanic men and especially in the South. Read More

Vanderbilt researchers are discovering ways that host proteins block HIV-1 infection, which could suggest new avenues for treatment. Read More

Researchers in the Vanderbilt Institute for Global Health are testing whether a unique “couples-centered” intervention developed in the southern African nation of Mozambique can reduce mother-to-child transmission of HIV. Read More

The first large study to report that HIV-infected people have a significantly higher risk of heart failure in the antiretroviral therapy era has been published in JAMA Cardiology. Read More

Traditional healers in sub-Saharan have a high rate of exposure to blood, putting them at risk for HIV and hepatitis C. Read More

Tuberculosis (TB) remains an important public health problem, particularly among people infected with the human immunodeficiency virus (HIV). Read More

This month an international HIV prevention trial was launched that is testing the infection-preventing prowess of a monoclonal antibody called VRCO1. Read More

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks. Read More

An international research team led by scientists from Vanderbilt University Medical Center has identified a genetic variant that protects people with HIV from developing active tuberculosis. The variant is near the gene encoding the infection-fighting cytokine IL-12. Read More

The first study to suggest that major depressive disorder (MDD) is an independent risk factor for heart failure in HIV-positive adults has been published in Circulation. Read More